Core Insights - Medtronic plc is expanding its global presence in the Cardiovascular business, which is expected to support growth in upcoming quarters [1] - The company is gaining market share in Neuroscience, particularly in Cranial and Spinal technologies, aided by strong growth and competitor exits [1] - International expansion remains robust, contributing significantly to revenue growth [1] Cardiovascular Business - Medtronic's cardiac rhythm management segment continues to lead the market, driven by strong performance in Defibrillation Solutions and cardiac pacing therapies [3] - The fiscal third quarter of 2025 saw the cardiovascular portfolio grow in the mid-single digits, with the Cardiac Ablation Solutions business achieving 22% growth [4] - The next-generation Micra AV2 and VR2 leadless pacemakers are key drivers of growth as they penetrate new and existing markets [3] Neuroscience Portfolio - The Neuroscience portfolio, particularly Cranial and Spinal technologies, is experiencing strong growth, with Medtronic gaining market share as competitors exit the market [5] - In Neuromodulation, the Inceptiv spinal cord stimulator drove 12% growth in the fiscal third quarter, while brain modulation saw 15% global growth and 26% growth in the U.S. [6] International Expansion - Nearly 49% of Medtronic's revenues were generated internationally in the third quarter of fiscal 2025, with emerging markets growing in high-single digits [7] - Significant growth was noted in India (high-teens), Eastern Europe (mid-teens), and low-double-digit growth in Southeast Asia, the Middle East, and Africa [9] Financial Performance - Medtronic has a market capitalization of $108.05 billion and an earnings yield of 6.92%, significantly higher than the industry's yield of 0.05% [2] - The Zacks Consensus Estimate for fiscal 2025 earnings per share (EPS) is $5.46, with revenues estimated at $33.48 billion, reflecting a 3.4% increase from the previous year [12]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $21.1 million, or 17 cents per diluted common share, compared to 20 cents per diluted common share in Q4 2024 [8][9] - Net interest income after provision expense was $96 million, up 4% from $92 million in Q4 2024 [10] - Non-interest expense for Q1 was $81.3 million, reflecting typical first-quarter increases in salary and employee benefits [10][25] Business Line Data and Key Metrics Changes - Total deposits increased to $14.5 billion, a 1% increase from the previous quarter, with a decrease in broker deposits to less than 7% of total deposits [13] - Loans receivable decreased to $13.3 billion, down 2% from year-end 2024, with residential mortgage loans increasing by 7% and commercial loans decreasing by 5% [14] - Loan production increased by 11% year-over-year, despite elevated paydowns and refinancing activities [15][16] Market Data and Key Metrics Changes - The company noted strong demand from Korean subsidiary sector customers, with an acceleration of direct investments in the U.S. by Korean companies [17][18] - The loan-to-value ratio for commercial real estate loans remained low at approximately 46% [19] Company Strategy and Development Direction - The company aims to strengthen its deposit base and position for prudent growth, focusing on organic loan growth and the integration of Territorial Bank [12][32] - The outlook for 2025 includes high single-digit percentage loan growth and mid-20s percentage growth in non-interest income, reflecting stronger momentum across fee income lines [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding macroeconomic volatility and the potential for a recession, but remains optimistic about loan demand from Korean customers [17][32] - The company expects net interest income growth to be in the high single-digit percentage range for 2025, revised from low double-digit growth expectations [33] Other Important Information - The merger with Territorial Bank was completed on April 2, 2025, contributing approximately $1.7 billion in stable low-cost deposits [11][12] - The company declared a quarterly common stock dividend of 14 cents per share, payable on May 16, 2025 [12] Q&A Session Summary Question: Impact of fewer rate cuts on NII growth outlook - Management indicated that fewer rate cuts would have a modest downward impact on NII, as the benefits of cutting deposit costs would offset the compression on variable rate loans [38][39] Question: Details on loan verticals for organic growth - Management highlighted positive momentum in pipelines for specialized commercial lending verticals, including healthcare and project finance, supported by recent team expansions [44] Question: Specific segments for loan growth in the second half - Management reiterated confidence in loan growth from Korean subsidiary sectors and specialized teams, with good momentum in their pipelines [48] Question: Asset quality and points of stress - Management reported stable asset quality and proactive monitoring of the portfolio, with borrowers diversifying supply chains to mitigate potential impacts from tariffs [52]